Atria Wealth Solutions Inc. Sells 4,959 Shares of Colgate-Palmolive (NYSE:CL)

Atria Wealth Solutions Inc. trimmed its position in Colgate-Palmolive (NYSE:CLFree Report) by 11.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,894 shares of the company’s stock after selling 4,959 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Colgate-Palmolive were worth $2,766,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of CL. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Colgate-Palmolive by 5.0% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 87,530 shares of the company’s stock valued at $6,224,000 after acquiring an additional 4,131 shares during the last quarter. FORVIS Wealth Advisors LLC raised its stake in shares of Colgate-Palmolive by 18.3% during the second quarter. FORVIS Wealth Advisors LLC now owns 21,443 shares of the company’s stock worth $1,652,000 after acquiring an additional 3,319 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Colgate-Palmolive by 0.5% during the second quarter. Victory Capital Management Inc. now owns 1,704,155 shares of the company’s stock worth $131,288,000 after acquiring an additional 8,383 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Colgate-Palmolive by 383.2% during the second quarter. IFP Advisors Inc now owns 12,944 shares of the company’s stock worth $811,000 after acquiring an additional 10,265 shares in the last quarter. Finally, Clearstead Advisors LLC increased its stake in shares of Colgate-Palmolive by 8.1% in the third quarter. Clearstead Advisors LLC now owns 30,556 shares of the company’s stock worth $2,173,000 after buying an additional 2,294 shares during the period. 78.36% of the stock is owned by hedge funds and other institutional investors.

Colgate-Palmolive Price Performance

NYSE CL opened at $83.46 on Friday. The company has a 50-day moving average price of $80.38 and a 200-day moving average price of $76.30. The firm has a market capitalization of $68.72 billion, a P/E ratio of 30.02, a PEG ratio of 3.69 and a beta of 0.42. Colgate-Palmolive has a 52 week low of $67.62 and a 52 week high of $86.14. The company has a quick ratio of 0.26, a current ratio of 0.41 and a debt-to-equity ratio of 21.40.

Colgate-Palmolive (NYSE:CLGet Free Report) last released its earnings results on Friday, January 26th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.02. The company had revenue of $4.95 billion during the quarter, compared to analyst estimates of $4.89 billion. Colgate-Palmolive had a net margin of 11.82% and a return on equity of 509.75%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.77 EPS. Equities research analysts anticipate that Colgate-Palmolive will post 3.48 earnings per share for the current year.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Monday, January 22nd will be paid a $0.48 dividend. The ex-dividend date is Friday, January 19th. This represents a $1.92 annualized dividend and a yield of 2.30%. Colgate-Palmolive’s payout ratio is 69.06%.

Insiders Place Their Bets

In other Colgate-Palmolive news, insider Jennifer Daniels sold 61,633 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.93, for a total value of $5,172,857.69. Following the completion of the transaction, the insider now directly owns 57,948 shares in the company, valued at approximately $4,863,575.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director C Martin Harris sold 2,760 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $84.50, for a total value of $233,220.00. Following the completion of the sale, the director now directly owns 19,272 shares in the company, valued at $1,628,484. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jennifer Daniels sold 61,633 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.93, for a total value of $5,172,857.69. Following the completion of the sale, the insider now owns 57,948 shares of the company’s stock, valued at $4,863,575.64. The disclosure for this sale can be found here. Insiders sold 92,123 shares of company stock worth $7,635,941 in the last three months. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently commented on CL shares. Bank of America raised shares of Colgate-Palmolive from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a research note on Friday, December 15th. UBS Group boosted their price objective on shares of Colgate-Palmolive from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, January 29th. JPMorgan Chase & Co. boosted their price objective on shares of Colgate-Palmolive from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, January 18th. Barclays boosted their price objective on shares of Colgate-Palmolive from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 16th. Finally, Stifel Nicolaus raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and reduced their price objective for the company from $85.00 to $81.00 in a research report on Monday, October 16th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.93.

View Our Latest Research Report on CL

Colgate-Palmolive Company Profile

(Free Report)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Featured Stories

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CLFree Report).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.